SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Life Scienc - Quaterly Results

10 Nov 2021 Evaluate
The September 2021 quarter revenue stood at Rs. 5617.61 millions, up 7.86% as compared to Rs. 5208.05 millions during the corresponding quarter last year.Net profit for the quarter ended September 2021 increased significantly by 58.96% to Rs. 1152.01 millions from Rs. 724.70 millions.Operating profit for the quarter ended September 2021 rose to 1694.26 millions as compared to 1269.30 millions of corresponding quarter ended September 2020.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202109 202009 % Var
Sales 5617.61 5208.05 7.86 5617.61 5208.05 7.86 5617.61 5208.05 7.86
Other Income 20.89 0.12 17308.33 20.89 0.12 17308.33 20.89 0.12 17308.33
PBIDT 1694.26 1269.30 33.48 1694.26 1269.30 33.48 1694.26 1269.30 33.48
Interest 72.26 219.04 -67.01 72.26 219.04 -67.01 72.26 219.04 -67.01
PBDT 1622.00 1050.26 54.44 1622.00 1050.26 54.44 1622.00 1050.26 54.44
Depreciation 96.65 83.49 15.76 96.65 83.49 15.76 96.65 83.49 15.76
PBT 1525.35 966.77 57.78 1525.35 966.77 57.78 1525.35 966.77 57.78
TAX 373.34 242.07 54.23 373.34 242.07 54.23 373.34 242.07 54.23
Deferred Tax 7.91 12.64 -37.42 7.91 12.64 -37.42 7.91 12.64 -37.42
PAT 1152.01 724.70 58.96 1152.01 724.70 58.96 1152.01 724.70 58.96
Equity 245.05 19.60 1150.26 245.05 19.60 1150.26 245.05 19.60 1150.26
PBIDTM(%) 30.16 24.37 23.75 30.16 24.37 23.75 30.16 24.37 23.75

Alivus Life Sciences Share Price

1156.95 -2.55 (-0.22%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: